Sosei, Fujifilm sales and marketing update
Sosei Group's Sosei Co. Ltd. subsidiary granted Fujifilm Holdings' Fujifilm Pharma Co. Ltd. subsidiary rights to commercialize SO-1105 in Japan. Under the deal, Sosei is responsible for registration, manufacturing and supply and Fujifilm is responsible for marketing and distribution. Sosei plans to submit an NDA for SO-1105 to treat oropharyngeal candidiasis in Japan next year. Sosei is eligible to receive ¥900 million ($8.8 million), comprised of an undisclosed upfront payment and development and regulatory milestones. Sosei said the milestones will be triggered by the filing of the NDA, regulatory approval and listing on Japan's National Health Insurance (NHI). Sosei is also eligible for an undisclosed amount in sales milestones, plus a "margin" on sales of SO-1105 in Japan. Fujifilm said it hopes to launch the product in its FY16 ending March 31, 2016. ...